|
|
|
|
|
|
About the Test
The RetnaGene AMD laboratory-developed test helps you to identify at-risk Caucasian patients, 55 years of age or older, who may progress to wet AMD, allowing you to individualize patient management.
RetnaGene AMD is a laboratory-developed genetic test to evaluate the risk of a patient with early or intermediate AMD progressing to advanced choroidal neovascular disease within 2, 5, and 10 years.
The reported risk scores for developing CNV are based on four risk factors:
-
Genotype: the genetic profile of 12 disease-associated single nucleotide polymorphisms (SNPs)
-
Phenotype: baseline simplified severity scale grade1 (as defined by the Age-Related Eye Disease Study2 [AREDS])
-
Age
-
Environment: smoking status
Contribution of Baseline Disease, Genetics, Smoking and Age to Population Risk of CNV in AREDS Subjects3
|
|
|
|
|
|
|
|
|